Interferon-free antiviral therapy for chronic hepatitis C


Sagalova O.I.

South Ural State Medical University Clinic, Ministry of Health of Russia, Chelyabinsk
Antiviral therapy for chronic hepatitis C (CHC) is undergoing revolutionary changes: standard dual therapy is being gradually substituted by the triple therapy regimens containing the direct-acting antivirals (DAAs), pegylated interferons and ribavirin. The safety and tolerability of dual and triple therapies are comparable. Novel DAAs combinations make possible to achieve a sustained virologic response in 90–100% of patients with CHC in shorter periods have been designed in recent years. Moreover, interferon-free antiviral regimens have a good safety profile, which allows their use in patients with cirrhosis and in those who have contraindications to interferon-containing therapy. The review presents the characteristics of the main classes of DAAs and the results of completed clinical trials of interferon-free regimens.

Literature



  1. Gower E., Estes C., Hindman S., Razavi-Shearer, K., Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus. J. Hepatol. 2014; 61(1S): 45–57.

  2. Hope V.D., Eramova I., Capurro D., Donoghoe M.C. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol. Infect. 2014; 142(2): 270–286.

  3. Пименов Н.Н., Чуланов В.П., Комарова С.В., Карандашова И.В., Неверов А Д., Михайловская Г.В., Долгин В.А., Лебедева Е.Б., Пашкина К.В., Коршунова Г.С. Гепатит С в России: эпидемиологическая характеристика и пути совершенствования диагностики и надзора. Эпидемиол. и инфекц. бол. 2012; (3): 4–9.

  4. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., Nyberg L.M., Lee W.M., Ghalib R.H., Schiff E.R., Galati J.S., Bacon B.R., Davis M.N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L.D., Brass C.A., Albrecht J.K., Sulkowski M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361(6): 580–593.

  5. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin. Ther. 2010; 32(13): 2117–2138.

  6. Hezode C., Fontaine H., Dorival C., Larrey D., Zoulim F., Canva V., de Ledinghen V., Poynard T., Samuel D., Bourlière M., Zarski J.P., Raabe J.J., Alric L., Marcellin P., Riachi G., Bernard P.H., Loustaud-Ratti V., Métivier S., Tran A., Serfaty L., Abergel A., Causse X., Di Martino V., Guyader D., Lucidarme D., Grando-Lemaire V., Hillon P., Feray C., Dao T., Cacoub P., Rosa I., Attali P., Petrov-Sanchez V., Barthe Y., Pawlotsky J.M., Pol S., Carrat F., Bronowicki J.P. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J. Hepatol. 2013; 59: 434–441.

  7. Perry C.M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012; 72(5): 619–641.

  8. Знойко О.О., Максимов С.Л., Маев И.В., Павлов Ч.С., Малышев Н.А., Блохина Н.П., Никитин И.Г., Михайлов М.И., Кожевникова Г.М., Лобзин Ю.В., Рахманова А.Г., Жданов К.В., Чуланов В.П., Шахгильдян И.В., Богомолов П.В., Мойсюк Я.Г., Чжао А.В., Андрейцева О.И. Рекомендации по диагностике и лечению взрослых больных гепатитом С. М., 2014. 91 с. http://arvt.ru/sites/default/files/rf-recom-gep-C-2014.pdf просмотрено 12.03.2015.

  9. Николаева Л.И. Вирус гепатита С: антигены вируса и реакция на них иммунной системы макроорганизма. Информационно-методическое пособие. Новосибирск: Вектор-Бест, 2009. 78 с.

  10. Meredith L.W., Zitzmann N., McKeating J.A. Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Antiviral Res. 2013; 100: 636–639.

  11. Schinazi R.F., Bassit L., Gavegnano C. HCV drug discovery aimed at viral eradication. J. Viral Hepat. 2010; 17: 77–90.

  12. Suk-Fong Lok A. HCV NS5A inhibitors in development. Clin. Liver Dis. 2013; 17: 111–121.

  13. El-Shamy A., Hak Hotta. Impact of hepatitis C virus heterogenecity on interferon sensitivity: An overview. World J. Gastroenterol. 2014; 20(24): 7555–7569.

  14. Sofia M.J., Bao D., Chang W., Du J., Nagarathnam D., Rachakonda S., Reddy P.G., Ross B.S., Wang P., Zhang H.R., Bansal S., Espiritu C., Keilman M., Lam A.M., Steuer H.M., Niu C., Otto M.J., Furman P.A. Discovery of a β-d-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 2010; 53: 7202–7218.

  15. Pawlotsky J.M. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin. Liver Dis. 2014; 34(1): 22–29.

  16. Rong L., Dahari H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2010; 2(30): 30–32.

  17. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterol. 2010; 138(2): 447–462.

  18. Nakamoto S., Kanda T., Wu S., Shirasawa H., Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J. Gastroenterol. 2014; 20(11): 2902–2912.

  19. Legrand-Abravanel F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs. 2010; 19 (8): 963–975.

  20. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therар. Adv. Gastroenterol. 2014; 7(3): 131–140.

  21. Haudecoeur R., Peuchmaur M., Ahmed-Belkacem A., Pawlotsky J.M., Boumendjel A. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research. Med. Res. Rev. 2013; 33 (5): 934–984.

  22. Pawlotsky J.M. NS5A inhibitors in the treatment of hepatitis C. J. Hepatol. 2013; 59 (2): 375–382.

  23. Dahari H., Guedj J., Perelson A.S., Layden T.J. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr. Hepat. Rep. 2011; 10(3): 214–227.

  24. Schmidt W.N., Nelson D.R., Pawlotsky J.M., Sherman K.E., Thomas D.L., Chung R.T. Direct-acting antiviral agents and the path to interferon independence. Clin. Gastroenterol. Hepatol. 2014; 12(5): 728–737.

  25. Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., Watanabe H., McPhee F., Hughes E., Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatolоgy 2012; 55: 742–748.

  26. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., Reindollar R., Rustgi V., McPhee F., Wind-Rotolo M., Persson A., Zhu K., Dimitrova D.I., Eley T., Guo T., Grasela D.M., Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype. N. Engl. J. Med. 2012; 366: 216–224.

  27. Suzuki Y., Ikeda K., Suzuki F., Toyota J., Karino Y., Chayama K., Kawakami Y., Ishikawa H., Watanabe H., Hu W., Eley T., McPhee F., Hughes E., Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 2013; 58: 655–662.

  28. Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H., Symonds W.T., McHutchison J.G., Membreno F.E. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotipe 1 hepatitis C virus infectoin (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383 (9916): 515–523.

  29. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., Romero-Gomez M., Zarski J.P., Agarwal K., Buggisch P., Foster G.R., Bräu N., Buti M., Jacobson I.M., Subramanian G.M., Ding X., Mo H., Yang J.C., Pang P.S., Symonds W.T., McHutchison J.G., Muir A.J., Mangia A., Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370(20): 1889–1898.

  30. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370(16):1483–1493.

  31. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., Lok A.S., Hinestrosa F., Thuluvath P.J., Schwartz H., Nelson D.R., Everson G.T., Eley T., Wind-Rotolo M., Huang S.P., Gao M., Hernandez D., McPhee F., Sherman D., Hindes R., Symonds W., Pasquinelli C., Grasela D.M. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370 (20): 1879–1888.

  32. Sulkowski M., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., Lawitz E., Lok A.S., Hinestrosa F., Thuluvath P.J., Schwartz H., Nelson D.R., Everson G.T., Eley T., Wind-Rotolo M., Huang S.P., Gao M., Hernandez D., McPhee F., Sherman D., Hindes R., Symonds W., Pasquinelli C., Grasela D.M. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370(3): 211–221.

  33. Pawlotsky J.M., Aghemo A., Dusheiko G., Forns X., Puoti M., Sarrazin C. EASL Recommendations on Treatment of Hepatitis C. 2014. doi: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html просмотрено 12.03.2015.

  34. Sulkowski M., Jacobson I.M., Ghalib R., Rodriguez-Torres M., Younossi Z., Corregidor A., Fevery B., Callewaert K., Symonds W., De La Rosa G., Picchio G., Ouwerkerk-Mahadevan S., Lambrecht T., Lawitz E. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis. 49th EASL. 9–13 April 2014, London. Oral abstract O7.

  35. Lawitz E., Sulkowski M., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., DeJesus E., Pearlman B., Rabinovitz M., Gitlin N., Lim J.K., Pockros P.J., Scott J.D., Fevery B., Lambrecht T., Ouwerkerk-Mahadevan S., Callewaert K., Symonds W.T., Picchio G., Lindsay K.L., Beumont M., Jacobson I.M. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384(9956): 1748.

  36. Kumada H., Suzuki Y., Ikeda K., Toyota J., Karino Y., Chayama K., Kawakami Y., Ido A., Yamamoto K., Takaguchi K., Izumi N., Koike K., Takehara T., Kawada N., Sata M., Miyagoshi H., Eley T., McPhee F., Damokosh A., Ishikawa H., Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59(6): 2083–2091.

  37. Manns M., Pol S., Jacobson I.M., Marcellin P., Gordon S.C., Peng C.Y., Chang T.T., Everson G.T., Heo J., Gerken G., Yoffe B., Towner W.J., Bourliere M., Metivier S., Chu C.J., Sievert W., Bronowicki J.P., Thabut D., Lee Y.J., Kao J.H., McPhee F., Kopit J., Mendez P., Linaberry M., Hughes E., Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384(9954): 1597–1605.

  38. Sims K.D., Lemm J., Eley T., Liu M., Berglind A., Sherman D., Lawitz E., Vutikullird A.B., Tebas P., Gao M., Pasquinelli C., Grasela D.M. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob. Agents Chemother. 2014; 58(6): 3496–3503.

  39. Everson G.T. Sims K.D., Rodriguez-Torres M., Hézode C., Lawitz E., Bourlière M., Loustaud-Ratti V., Rustgi V., Schwartz H., Tatum H., Marcellin P., Pol S., Thuluvath P.J., Eley T., Wang X., Huang S.P., McPhee F., Wind-Rotolo M., Chung E., Pasquinelli C., Grasela D.M., Gardiner D.F. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146(2): 420–429.

  40. Lawitz E., Gane E., Pearlman B., Tam E., Ghesquiere W., Guyader D., Alric L., Bronowicki J.P., Lester L., Sievert W., Ghalib R., Balart L., Sund F., Lagging M., Dutko F., Shaughnessy M., Hwang P., Howe A.Y., Wahl J., Robertson M., Barr E., Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014. doi:10.1016/S0140-6736(14)61795-5.

  41. Kowdley K.V., Lawitz E., Poordad F., Cohen D.E., Nelson D.R., Zeuzem S., Everson G.T., Kwo P., Foster G.R., Sulkowski M.S., Xie W., Pilot-Matias T., Liossis G., Larsen L., Khatri A., Podsadecki T., Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N. Engl. J. Med. 2014; 370: 222–232.

  42. Feld J.J., Kowdley K.V., Coakley E., Sigal S., Nelson D.R., Crawford D., Weiland O., Aguilar H., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B. Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin. N. Engl. J. Med. 2014; 370: 1594–1603.

  43. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C., Tam E., Marinho R.T., Tsai N., Nyberg A., Box T.D., Younes Z., Enayati P., Green S., Baruch Y., Bhandari B.R., Caruntu F.A., Sepe T., Chulanov V., Janczewska E., Rizzardini G., Gervain J., Planas R., Moreno C., Hassanein T., Xie W., King M., Podsadecki T., Reddy K.R. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014; 370(21): 1983–1992.

  44. Zeuzem S., Jacobson I.M., Baykal T., Marinho R.T., Poordad F., Bourlière M., Sulkowski M.S., Wedemeyer H., Tam E., Desmond P., Jensen D.M., Di Bisceglie A.M., Varunok P., Hassanein T., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1604–1614.

  45. Andreone P., Colombo M.G., Enejosa J.V., Koksal I., Ferenci P., Maieron A., Müllhaupt B., Horsmans Y., Weiland O., Reesink H.W., Rodrigues L.Jr., Hu Y.B., Podsadecki T., Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterolоgy 2014; 147(2): 359–365.

  46. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., Shiffman M.L., Wedemeyer H., Berg T., Yoshida E.M., Forns X., Lovell S.S., Da Silva-Tillmann B., Collins C.A., Campbell A.L., Podsadecki T., Bernstein B. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014; 370: 1973–1982.

  47. Colombo M., Weiland O., Cohen D.E., Xie W., Baykal T., Enejosa J., Coakley E, Trinh R., Podsadecki T., DuFour J.J., Reynaert H., Diago M., Villa E., Streinu-Cercel A. SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology 2014; 60:(Suppl 1): 807A. Аbstract #1931.

  48. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., Schultz M., Davis M.N., Kayali Z., Reddy K.R., Jacobson I.M., Kowdley K.V., Nyberg L., Subramanian G.M., Hyland R.H., Arterburn S., Jiang D., McNally J., Brainard D., Symonds W.T., McHutchison J.G., Sheikh A.M., Younossi Z., Gane E.J. Sofosbuvir for previously untreated chronic Hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878–1887.

  49. Zeuzem S., Dusheiko G.M., Salupere R., Mangia A., Flisiak R., Hyland R.H., Illeperuma A., Svarovskaia E., Brainard D.M., Symonds W.T., Subramanian G.M., McHutchison J.G., Weiland O., Reesink H.W., Ferenci P., Hézode C., Esteban R. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N. Engl. J. Med. 2014; 370: 1993–2001.


About the Autors


For сorrespondence:
Sagalova Olga Igorevna, MD; Head, Infectious Diseases Department Two, South Ural State Medical University Clinic, Ministry of Health of Russia
Address: 2, Cherkasskaya St, Chelyabinsk 454052
Telephone: +7(351) 721-82-02
E-mail: olga_sagalova@mail.ru


Similar Articles


Бионика Медиа